A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 166 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-10.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 49 in phase 3, and was the 40th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 721 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 54th largest by enrollment of the 428 interventional ones that give a count, is one of 22 that started in 2014, is one of 187 in phase 3, and was the 370th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs) excluding SUs (sulfonylureas)/glinides in subjects with type 2 diabetes.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 721 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - Male or female, age at least 18 years at the time of signing - Subjects fulfilling at least one of the below criteria: a) Experienced at least one severe hypoglycaemic episode within last year (according to the ADA (American Diabetes Association) definition, April 2013), b) Moderate chronic renal failure, defined as 30 - 59 mL/min/1.73 m\^2 per CKD-Epi (Chronic Kidney Disease Epidemiology Collaboration) by central laboratory analysis, c) Hypoglycaemic symptom unawareness, d) Exposed to insulin for more than 5 years, e) Recent episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose measurement (below or equal to 70 mg/dL [below or equal to 3.9 mmol/L])) within the last 12 weeks prior to Visit 1 (screening) - Type 2 diabetes mellitus (diagnosed clinically) for at least 26 weeks prior to Visit 1 - Current treatment with any basal insulin (OD or BID) ± any combination of OADs (metformin, DPP-4 inhibitor, alpha-glucosidase inhibitor, thiazolidinediones, and SGLT2-inhibitor) for 26 weeks or longer prior to Visit 1 For subjects on BID the total daily dose should be below 75 units - (glycosylated ) below or equal to 9.5 % by central laboratory analysis - (body mass index) below or equal to 45 kg/m\^2 Exclusion Criteria: - Treatment with a bolus insulin separately or contained in an insulin mix product within the last 26 weeks prior to Visit 1 - Use of any other anti-diabetic agent(s) than those stated in the inclusion criteria within the last 26 weeks prior to Visit 1
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
Drug: insulin degludec · Drug: insulin glargine
The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
Drug: insulin degludec · Drug: insulin glargine
Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period
Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.
Time frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episode During the Maintenance Period
Severe or BG confirmed symptomatic nocturnal hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia and with time of onset between 00:01 and 05.59 a.m., both inclusive. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.
Time frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)
Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period
Percentage of subjects who experienced one or more severe hypoglycaemic episodes during the maintenance period. Severe hypoglycaemia (according to the American Diabetes Association 2013 definition): A hypoglycaemic episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose values may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)
Incidence of Treatment Emergent Adverse Events
Treatment emergent adverse event was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.
Time frame: During 32 weeks of treatment for each treatment period
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Change from baseline in HbA1c (glycosylated haemoglobin) at week 32 (treatment period 1) and at week 64 (treatment period 2). Week 32 HbA1c value was considered as baseline for calculating change from baseline in HbA1c at week 64.
Time frame: Week 32, Week 64
FPG (Fasting Plasma Glucose)
Fasting plasma glucose values at week 32 and week 64.
Time frame: week 32, week 64
The trial was conducted at 152 sites in the United States.
| Milestone | Insulin Degludec/Insulin Glargine (IDeg/IGlar) | Insulin Glargine/Insulin Degludec (IGlar/IDeg) |
|---|---|---|
| Started | 361 | 360 |
| Exposed | 356 | 357 |
| Completed | 308 | 315 |
| Not completed | 53 | 45 |
| Withdrew: Adverse event | 5 | 7 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 11 | 3 |
| Withdrew: Protocol violation | 22 | 17 |
| Withdrew: Withdrawal by subject | 13 | 17 |
| Withdrew: Casebook unsigned | 1 | 0 |
| Withdrew: Unclassified | 1 | 0 |
| Milestone | Insulin Degludec/Insulin Glargine (IDeg/IGlar) | Insulin Glargine/Insulin Degludec (IGlar/IDeg) |
|---|---|---|
| Started | 308 | 315 |
| Completed | 283 | 297 |
| Not completed | 25 | 18 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 13 | 9 |
| Withdrew: Unclassified | 1 | 0 |
Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.
| events | Insulin Degludec (IDeg) | Insulin Glargine (IGlar) |
|---|---|---|
| Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period | 353 | 496 |
Severe or BG confirmed symptomatic nocturnal hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia and with time of onset between 00:01 and 05.59 a.m., both inclusive. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.
| events | Insulin Degludec (IDeg) | Insulin Glargine (IGlar) |
|---|---|---|
| Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episode During the Maintenance Period | 105 | 175 |
Percentage of subjects who experienced one or more severe hypoglycaemic episodes during the maintenance period. Severe hypoglycaemia (according to the American Diabetes Association 2013 definition): A hypoglycaemic episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose values may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
| percentage of subjects | Insulin Degludec (IDeg) | Insulin Glargine (IGlar) |
|---|---|---|
| Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period | 1.6 | 2.4 |
Treatment emergent adverse event was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.
| events | Insulin Degludec (IDeg) | Insulin Glargine (IGlar) |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events | 1293 | 1381 |
Change from baseline in HbA1c (glycosylated haemoglobin) at week 32 (treatment period 1) and at week 64 (treatment period 2). Week 32 HbA1c value was considered as baseline for calculating change from baseline in HbA1c at week 64.
| percentage of glycosylated haemoglobin | Insulin Degludec/Insulin Glargine (IDeg/IGlar) | Insulin Glargine/Insulin Degludec (IGlar/IDeg) |
|---|---|---|
| week 32 (n=308, 313) | -0.49 ± 0.99 | -0.58 ± 1.02 |
| week 64 (n=295, 301) | 0.03 ± 0.75 | 0.10 ± 0.83 |
Fasting plasma glucose values at week 32 and week 64.
| mg/dL | Insulin Degludec/Insulin Glargine (IDeg/IGlar) | Insulin Glargine/Insulin Degludec (IGlar/IDeg) |
|---|---|---|
| week 32 (n=307, 311) | 107.33 ± 41.72 | 106.96 ± 39.81 |
| week 64 (n=293, 302) | 114.07 ± 51.91 | 107.55 ± 51.30 |
Collected over From the first day of exposure to randomised treatment and no later than the last day of randomised treatment (64 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec (IDeg) | — | 64/671 (9.5%) | 93/671 (13.9%) |
| Insulin Glargine (IGlar) | — | 65/665 (9.8%) | 77/665 (11.6%) |
| Event | Insulin Degludec (IDeg) | Insulin Glargine (IGlar) |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 2/671 | 9/665 |
| Angina pectorisCardiac disorders | 1/671 | 4/665 |
| SepsisInfections and infestations | 1/671 | 4/665 |
| Coronary artery diseaseCardiac disorders | 2/671 | 3/665 |
| Non-cardiac chest painGeneral disorders | 3/671 | 3/665 |
| Angina unstableCardiac disorders | 0/671 | 2/665 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/671 | 2/665 |
| Cardiac failure congestiveCardiac disorders | 1/671 | 2/665 |
| Renal cystRenal and urinary disorders | 0/671 | 2/665 |
| Transient ischaemic attackNervous system disorders | 0/671 | 2/665 |
| Event | Insulin Degludec (IDeg) | Insulin Glargine (IGlar) |
|---|---|---|
| NasopharyngitisInfections and infestations | 50/671 | 41/665 |
| Upper respiratory tract infectionInfections and infestations | 44/671 | 37/665 |
Full analysis set included all randomised subjects. One subject was excluded from the analysis due to unsigned casebook.
| Age, Continuous(years) | Insulin Degludec/Insulin Glargine (IDeg/IGlar) | Insulin Glargine/Insulin Degludec (IGlar/IDeg) | Total |
|---|---|---|---|
| Mean | 61.5 ± 10.7 | 61.2 ± 10.3 | 61.4 ± 10.5 |
| Sex: Female, Male(Participants) | Insulin Degludec/Insulin Glargine (IDeg/IGlar) | Insulin Glargine/Insulin Degludec (IGlar/IDeg) | Total |
|---|---|---|---|
| Female | 169 | 169 | 338 |
| Male | 191 | 191 | 382 |
| Glycosylated haemoglobin(percentage of glycosylated haemoglobin) | Insulin Degludec/Insulin Glargine (IDeg/IGlar) | Insulin Glargine/Insulin Degludec (IGlar/IDeg) | Total |
|---|---|---|---|
| Mean | 7.6 ± 1.1 | 7.6 ± 1.1 | 7.6 ± 1.1 |
| Fasting plasma glucose(mg/dL) | Insulin Degludec/Insulin Glargine (IDeg/IGlar) | Insulin Glargine/Insulin Degludec (IGlar/IDeg) | Total |
|---|---|---|---|
| Mean | 139.2 ± 53.5 | 134.9 ± 51.6 | 137.0 ± 52.6 |
Showing the first 100 of 166 sites across 2 countries. Choose a country and city above to see the rest.
Ran from Jan 2014 to primary completion in Dec 2015, 22 months.
Results were first posted in Jan 2017, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Glargine